Dr. Huang to guide preclinical and clinical investigation of resolvin-based therapies in solid tumor cancers Ridgefield, CT – (October 13, 2021) – Thetis Pharmaceuticals LLC (“Thetis”), a biopharmaceutical company developing Resolvin-based therapies to treat cancer and autoimmune diseases, announced today that Dr. Sui Huang has joined its Scientific Advisory Board. Dr. Huang is a molecular […]